Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 218 entries
Sorted by: Best Match Show Resources per page
Estrogen receptor-mediated neuroprotection: The role of the Alzheimer's disease-related gene seladin-1.

Neuropsychiatric disease and treatment

Peri A, Serio M.
PMID: 19043524
Neuropsychiatr Dis Treat. 2008 Aug;4(4):817-24. doi: 10.2147/ndt.s3637.

Experimental evidence supports a protective role of estrogen in the brain. According to the fact that Alzheimer's disease (AD) is more common in postmenopausal women, estrogen treatment has been proposed. However, there is no general consensus on the beneficial...

Cite
Peri A, Serio M. Estrogen receptor-mediated neuroprotection: The role of the Alzheimer's disease-related gene seladin-1. Neuropsychiatr Dis Treat. 2008;4(4):817-24doi: 10.2147/ndt.s3637.
Peri, A., & Serio, M. (2008). Estrogen receptor-mediated neuroprotection: The role of the Alzheimer's disease-related gene seladin-1. Neuropsychiatric disease and treatment, 4(4), 817-24. https://doi.org/10.2147/ndt.s3637
Peri, Alessandro, and Serio, Mario. "Estrogen receptor-mediated neuroprotection: The role of the Alzheimer's disease-related gene seladin-1." Neuropsychiatric disease and treatment vol. 4,4 (2008): 817-24. doi: https://doi.org/10.2147/ndt.s3637
Peri A, Serio M. Estrogen receptor-mediated neuroprotection: The role of the Alzheimer's disease-related gene seladin-1. Neuropsychiatr Dis Treat. 2008 Aug;4(4):817-24. doi: 10.2147/ndt.s3637. PMID: 19043524; PMCID: PMC2536547.
Copy Download .nbib Format: NLM
Selective estrogen receptor modulators.

IDrugs : the investigational drugs journal

Rotella DP.
PMID: 16096913
IDrugs. 2000 Jun;3(6):589-90.

No abstract available.

Cite
Rotella DP. Selective estrogen receptor modulators. IDrugs. 2000;3(6):589-90
Rotella, D. P. (2000). Selective estrogen receptor modulators. IDrugs : the investigational drugs journal, 3(6), 589-90.
Rotella, D P. "Selective estrogen receptor modulators." IDrugs : the investigational drugs journal vol. 3,6 (2000): 589-90.
Rotella DP. Selective estrogen receptor modulators. IDrugs. 2000 Jun;3(6):589-90. PMID: 16096913.
Copy Download .nbib Format: NLM
Osteoporosis: understanding key risk factors and therapeutic options.

The Physician and sportsmedicine

Beck BR, Shoemaker MR.
PMID: 20086622
Phys Sportsmed. 2000 Feb;28(2):69-84. doi: 10.3810/psm.2000.02.695.

Bone loss throughout life is a normal consequence of aging; however, some people are more predisposed to developing osteoporosis and sustaining associated fractures than others. But the risk of osteoporosis can be reduced by: (1) maximizing skeletal mass during...

Cite
Beck BR, Shoemaker MR. Osteoporosis: understanding key risk factors and therapeutic options. Phys Sportsmed. 2000;28(2):69-84doi: 10.3810/psm.2000.02.695.
Beck, B. R., & Shoemaker, M. R. (2000). Osteoporosis: understanding key risk factors and therapeutic options. The Physician and sportsmedicine, 28(2), 69-84. https://doi.org/10.3810/psm.2000.02.695
Beck, B R, and Shoemaker, M R. "Osteoporosis: understanding key risk factors and therapeutic options." The Physician and sportsmedicine vol. 28,2 (2000): 69-84. doi: https://doi.org/10.3810/psm.2000.02.695
Beck BR, Shoemaker MR. Osteoporosis: understanding key risk factors and therapeutic options. Phys Sportsmed. 2000 Feb;28(2):69-84. doi: 10.3810/psm.2000.02.695. PMID: 20086622.
Copy Download .nbib Format: NLM
Bazedoxifene: the evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosis.

Therapeutic advances in musculoskeletal disease

Komm BS, Chines AA.
PMID: 22870492
Ther Adv Musculoskelet Dis. 2012 Feb;4(1):21-34. doi: 10.1177/1759720X11422602.

Osteoporosis is a significant public health concern, particularly for postmenopausal women. Current treatment options may not be appropriate for all women. Selective estrogen-receptor modulators (SERMs) are a class of molecules with tissue-selective activity. Bazedoxifene is currently in clinical development...

Cite
Komm BS, Chines AA. Bazedoxifene: the evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosis. Ther Adv Musculoskelet Dis. 2012;4(1):21-34doi: 10.1177/1759720X11422602.
Komm, B. S., & Chines, A. A. (2012). Bazedoxifene: the evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosis. Therapeutic advances in musculoskeletal disease, 4(1), 21-34. https://doi.org/10.1177/1759720X11422602
Komm, Barry S, and Chines, Arkadi A. "Bazedoxifene: the evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosis." Therapeutic advances in musculoskeletal disease vol. 4,1 (2012): 21-34. doi: https://doi.org/10.1177/1759720X11422602
Komm BS, Chines AA. Bazedoxifene: the evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosis. Ther Adv Musculoskelet Dis. 2012 Feb;4(1):21-34. doi: 10.1177/1759720X11422602. PMID: 22870492; PMCID: PMC3383524.
Copy Download .nbib Format: NLM
Lasofoxifene (CP-336,156), a novel selective estrogen receptor modulator, in preclinical studies.

Journal of the American Aging Association

Ke HZ, Brown TA, Thompson DD.
PMID: 23604900
J Am Aging Assoc. 2002 Apr;25(2):87-99. doi: 10.1007/s11357-002-0007-y.

Estrogen replacement therapy is reported to reduce the incidence of vertebral fractures in postmenopausal women, however, its compliance is limited because of side effects and safety concerns. Estrogen's side effects on breast and uterine tissues leading to the potential...

Cite
Ke HZ, Brown TA, Thompson DD. Lasofoxifene (CP-336,156), a novel selective estrogen receptor modulator, in preclinical studies. J Am Aging Assoc. 2002;25(2):87-99doi: 10.1007/s11357-002-0007-y.
Ke, H. Z., Brown, T. A., & Thompson, D. D. (2002). Lasofoxifene (CP-336,156), a novel selective estrogen receptor modulator, in preclinical studies. Journal of the American Aging Association, 25(2), 87-99. https://doi.org/10.1007/s11357-002-0007-y
Ke, H Z, et al. "Lasofoxifene (CP-336,156), a novel selective estrogen receptor modulator, in preclinical studies." Journal of the American Aging Association vol. 25,2 (2002): 87-99. doi: https://doi.org/10.1007/s11357-002-0007-y
Ke HZ, Brown TA, Thompson DD. Lasofoxifene (CP-336,156), a novel selective estrogen receptor modulator, in preclinical studies. J Am Aging Assoc. 2002 Apr;25(2):87-99. doi: 10.1007/s11357-002-0007-y. PMID: 23604900; PMCID: PMC3455753.
Copy Download .nbib Format: NLM
Influence of Supplementary Vitamin D on Bone Mineral Density When Used in Combination with Selective Estrogen Receptor Modulators.

Journal of menopausal medicine

Liu HJ, Kim SA, Shim DJ, Jung JM, Lee EJ.
PMID: 31497579
J Menopausal Med. 2019 Aug;25(2):94-99. doi: 10.6118/jmm.19193. Epub 2019 Jul 23.

OBJECTIVES: Vitamin D is regarded as one of the major nutrients that significantly influence bone metabolism. This study aims to look at the effect of supplementary vitamin D on bone mineral density (BMD) in female osteoporosis patients.METHODS: The retrospective...

Cite
Liu HJ, Kim SA, Shim DJ, et al. Influence of Supplementary Vitamin D on Bone Mineral Density When Used in Combination with Selective Estrogen Receptor Modulators. J Menopausal Med. 2019;25(2):94-99doi: 10.6118/jmm.19193.
Liu, H. J., Kim, S. A., Shim, D. J., Jung, J. M., & Lee, E. J. (2019). Influence of Supplementary Vitamin D on Bone Mineral Density When Used in Combination with Selective Estrogen Receptor Modulators. Journal of menopausal medicine, 25(2), 94-99. https://doi.org/10.6118/jmm.19193
Liu, Hyun Ju, et al. "Influence of Supplementary Vitamin D on Bone Mineral Density When Used in Combination with Selective Estrogen Receptor Modulators." Journal of menopausal medicine vol. 25,2 (2019): 94-99. doi: https://doi.org/10.6118/jmm.19193
Liu HJ, Kim SA, Shim DJ, Jung JM, Lee EJ. Influence of Supplementary Vitamin D on Bone Mineral Density When Used in Combination with Selective Estrogen Receptor Modulators. J Menopausal Med. 2019 Aug;25(2):94-99. doi: 10.6118/jmm.19193. Epub 2019 Jul 23. PMID: 31497579; PMCID: PMC6718647.
Copy Download .nbib Format: NLM
Current medical treatment of estrogen receptor-positive breast cancer.

World journal of biological chemistry

Lumachi F, Santeufemia DA, Basso SM.
PMID: 26322178
World J Biol Chem. 2015 Aug 26;6(3):231-9. doi: 10.4331/wjbc.v6.i3.231.

Approximately 80% of breast cancers (BC) are estrogen receptor (ER)-positive and thus endocrine therapy (ET) should be considered complementary to surgery in the majority of patients. The advantages of oophorectomy, adrenalectomy and hypophysectomy in women with advanced BC have...

Cite
Lumachi F, Santeufemia DA, Basso SM. Current medical treatment of estrogen receptor-positive breast cancer. World J Biol Chem. 2015;6(3):231-9doi: 10.4331/wjbc.v6.i3.231.
Lumachi, F., Santeufemia, D. A., & Basso, S. M. (2015). Current medical treatment of estrogen receptor-positive breast cancer. World journal of biological chemistry, 6(3), 231-9. https://doi.org/10.4331/wjbc.v6.i3.231
Lumachi, Franco, et al. "Current medical treatment of estrogen receptor-positive breast cancer." World journal of biological chemistry vol. 6,3 (2015): 231-9. doi: https://doi.org/10.4331/wjbc.v6.i3.231
Lumachi F, Santeufemia DA, Basso SM. Current medical treatment of estrogen receptor-positive breast cancer. World J Biol Chem. 2015 Aug 26;6(3):231-9. doi: 10.4331/wjbc.v6.i3.231. PMID: 26322178; PMCID: PMC4549764.
Copy Download .nbib Format: NLM
The guiding role of bone metabolism test in osteoporosis treatment.

American journal of clinical and experimental immunology

Zhang W, Yang GJ, Wu SX, Li DQ, Xu YB, Ma CH, Wang JL, Chen WW.
PMID: 29755856
Am J Clin Exp Immunol. 2018 Apr 05;7(2):40-49. eCollection 2018.

Osteoporosis (OP) and osteoporotic fractures are becoming a serious health care issue in the world. Calcium and vitamin D are the basic treatment for osteoporosis. Nonetheless, they do not effectively reduce the incidences of fracture. Currently approved treatments for...

Cite
Zhang W, Yang GJ, Wu SX, et al. The guiding role of bone metabolism test in osteoporosis treatment. Am J Clin Exp Immunol. 2018;7(2):40-49
Zhang, W., Yang, G. J., Wu, S. X., Li, D. Q., Xu, Y. B., Ma, C. H., Wang, J. L., & Chen, W. W. (2018). The guiding role of bone metabolism test in osteoporosis treatment. American journal of clinical and experimental immunology, 7(2), 40-49.
Zhang, Wei, et al. "The guiding role of bone metabolism test in osteoporosis treatment." American journal of clinical and experimental immunology vol. 7,2 (2018): 40-49.
Zhang W, Yang GJ, Wu SX, Li DQ, Xu YB, Ma CH, Wang JL, Chen WW. The guiding role of bone metabolism test in osteoporosis treatment. Am J Clin Exp Immunol. 2018 Apr 05;7(2):40-49. eCollection 2018. PMID: 29755856; PMCID: PMC5944817.
Copy Download .nbib Format: NLM
Lifestyle Interventions for Breast Cancer Prevention.

Current breast cancer reports

Brown JC, Ligibel JA.
PMID: 30713591
Curr Breast Cancer Rep. 2018 Sep;10(3):202-208. doi: 10.1007/s12609-018-0281-z. Epub 2018 Jul 03.

One-in-eight women in the United States will develop breast cancer in her lifetime. Despite the established efficacy of selective estrogen receptor modulators and aromatase inhibitors in reducing the risk of developing hormone receptor positive breast cancer, use of these...

Cite
Brown JC, Ligibel JA. Lifestyle Interventions for Breast Cancer Prevention. Curr Breast Cancer Rep. 2018;10(3):202-208doi: 10.1007/s12609-018-0281-z.
Brown, J. C., & Ligibel, J. A. (2018). Lifestyle Interventions for Breast Cancer Prevention. Current breast cancer reports, 10(3), 202-208. https://doi.org/10.1007/s12609-018-0281-z
Brown, Justin C, and Ligibel, Jennifer A. "Lifestyle Interventions for Breast Cancer Prevention." Current breast cancer reports vol. 10,3 (2018): 202-208. doi: https://doi.org/10.1007/s12609-018-0281-z
Brown JC, Ligibel JA. Lifestyle Interventions for Breast Cancer Prevention. Curr Breast Cancer Rep. 2018 Sep;10(3):202-208. doi: 10.1007/s12609-018-0281-z. Epub 2018 Jul 03. PMID: 30713591; PMCID: PMC6350793.
Copy Download .nbib Format: NLM
The impact of different strategies to handle missing data on both precision and bias in a drug safety study: a multidatabase multinational population-based cohort study.

Clinical epidemiology

Martín-Merino E, Calderón-Larrañaga A, Hawley S, Poblador-Plou B, Llorente-García A, Petersen I, Prieto-Alhambra D.
PMID: 29892204
Clin Epidemiol. 2018 Jun 05;10:643-654. doi: 10.2147/CLEP.S154914. eCollection 2018.

BACKGROUND: Missing data are often an issue in electronic medical records (EMRs) research. However, there are many ways that people deal with missing data in drug safety studies.AIM: To compare the risk estimates resulting from different strategies for the...

Cite
Martín-Merino E, Calderón-Larrañaga A, Hawley S, et al. The impact of different strategies to handle missing data on both precision and bias in a drug safety study: a multidatabase multinational population-based cohort study. Clin Epidemiol. 2018;10:643-654doi: 10.2147/CLEP.S154914.
Martín-Merino, E., Calderón-Larrañaga, A., Hawley, S., Poblador-Plou, B., Llorente-García, A., Petersen, I., & Prieto-Alhambra, D. (2018). The impact of different strategies to handle missing data on both precision and bias in a drug safety study: a multidatabase multinational population-based cohort study. Clinical epidemiology, 10643-654. https://doi.org/10.2147/CLEP.S154914
Martín-Merino, Elisa, et al. "The impact of different strategies to handle missing data on both precision and bias in a drug safety study: a multidatabase multinational population-based cohort study." Clinical epidemiology vol. 10 (2018): 643-654. doi: https://doi.org/10.2147/CLEP.S154914
Martín-Merino E, Calderón-Larrañaga A, Hawley S, Poblador-Plou B, Llorente-García A, Petersen I, Prieto-Alhambra D. The impact of different strategies to handle missing data on both precision and bias in a drug safety study: a multidatabase multinational population-based cohort study. Clin Epidemiol. 2018 Jun 05;10:643-654. doi: 10.2147/CLEP.S154914. eCollection 2018. PMID: 29892204; PMCID: PMC5993167.
Copy Download .nbib Format: NLM
Dual targeting of estrogen receptor α and estrogen-related receptor α: a novel endocrine therapy for endometrial cancer.

OncoTargets and therapy

Mao X, Dong B, Gao M, Ruan G, Huang M, Braicu EI, Sehouli J, Sun P.
PMID: 31686835
Onco Targets Ther. 2019 Aug 20;12:6757-6767. doi: 10.2147/OTT.S216146. eCollection 2019.

BACKGROUND: Endometrial cancer (EC) is a hormone dependent carcinoma that may involve complex molecular mechanisms. Endocrine therapy by blocking the estrogen and estrogen receptor α (ERα) has been effective in breast cancer, while it is still controversial in EC....

Cite
Mao X, Dong B, Gao M, et al. Dual targeting of estrogen receptor α and estrogen-related receptor α: a novel endocrine therapy for endometrial cancer. Onco Targets Ther. 2019;12:6757-6767doi: 10.2147/OTT.S216146.
Mao, X., Dong, B., Gao, M., Ruan, G., Huang, M., Braicu, E. I., Sehouli, J., & Sun, P. (2019). Dual targeting of estrogen receptor α and estrogen-related receptor α: a novel endocrine therapy for endometrial cancer. OncoTargets and therapy, 126757-6767. https://doi.org/10.2147/OTT.S216146
Mao, XiaoDan, et al. "Dual targeting of estrogen receptor α and estrogen-related receptor α: a novel endocrine therapy for endometrial cancer." OncoTargets and therapy vol. 12 (2019): 6757-6767. doi: https://doi.org/10.2147/OTT.S216146
Mao X, Dong B, Gao M, Ruan G, Huang M, Braicu EI, Sehouli J, Sun P. Dual targeting of estrogen receptor α and estrogen-related receptor α: a novel endocrine therapy for endometrial cancer. Onco Targets Ther. 2019 Aug 20;12:6757-6767. doi: 10.2147/OTT.S216146. eCollection 2019. PMID: 31686835; PMCID: PMC6709363.
Copy Download .nbib Format: NLM
Molecular mechanisms of estrogen action in female genital tract development.

Differentiation; research in biological diversity

Alderman MH, Taylor HS.
PMID: 33707128
Differentiation. 2021 Mar-Apr;118:34-40. doi: 10.1016/j.diff.2021.01.002. Epub 2021 Feb 24.

The development of the female reproductive tract can be divided into three parts consisting of Müllerian duct organogenesis, pre-sexual maturation organ development, and post-sexual maturation hormonal regulation. In primates, Müllerian duct organogenesis proceeds in an estrogen independent fashion based...

Cite
Alderman MH, Taylor HS. Molecular mechanisms of estrogen action in female genital tract development. Differentiation. 2021;118:34-40doi: 10.1016/j.diff.2021.01.002.
Alderman, M. H., & Taylor, H. S. (2021). Molecular mechanisms of estrogen action in female genital tract development. Differentiation; research in biological diversity, 11834-40. https://doi.org/10.1016/j.diff.2021.01.002
Alderman, Myles H, and Taylor, Hugh S. "Molecular mechanisms of estrogen action in female genital tract development." Differentiation; research in biological diversity vol. 118 (2021): 34-40. doi: https://doi.org/10.1016/j.diff.2021.01.002
Alderman MH, Taylor HS. Molecular mechanisms of estrogen action in female genital tract development. Differentiation. 2021 Mar-Apr;118:34-40. doi: 10.1016/j.diff.2021.01.002. Epub 2021 Feb 24. PMID: 33707128; PMCID: PMC8073215.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 218 entries